In comparison, Gemcitabine showed almost no inhibitory effect on CCA tumors, while ICAM1 antibodies showed a certain inhibitory effect on tumor growth, but was significantly less effective than ICAM1-MMAE and ICAM1-DXd treatments. This evidence concerns the gene ICAM1 and cholangiocarcinoma.